Compare Antengene Corporation Limited (722) vs. Competitors

0 Followers

Comparison Results

722

Antengene Corporation Limited

€0.53

€247.63M

37.67

-49.14%

2 Buy

0 Hold

0 Sell

Moderate Buy

Innovent Biologics

HK$100.10

HK$169.77B

119.83

-1.14%

22 Buy

0 Hold

0 Sell

Strong Buy

Alphamab Oncology

HK$11.90

HK$8.18B

-41.62

-45.34%

―

Shanghai Junshi Biosciences Co., Ltd. Class H

HK$27.54

HK$36.56B

-83.16

-40.35%

2 Buy

1 Hold

0 Sell

Moderate Buy

CStone Pharmaceuticals

HK$5.34

HK$8.92B

-18.50

-25.38%

1 Buy

0 Hold

0 Sell

Moderate Buy

Ascentage Pharma Group International

HK$50.90

HK$10.39B

-6.76

-60.34%

1 Buy

0 Hold

0 Sell

Moderate Buy

xxxxxxxxxxxxx

722 vs 6855

xxxxxxxxxxxxx

Performance Comparison

DE:722

Antengene Corporation Limited

0.36

-0.36

-50.21%

HK:1801

Innovent Biologics

99.35

-5.35

-5.11%

HK:9966

Alphamab Oncology

8.38

-6.32

-42.99%

HK:1877

Shanghai Junshi Biosciences Co., Ltd. Class H

18.54

-13.06

-41.33%

HK:2616

CStone Pharmaceuticals

5.85

-2.35

-28.66%

HK:6855

Ascentage Pharma Group International

30.78

-47.32

-60.59%

Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts

Compare More Stocks >